Reviewing the past 12 months and looking to the future in GPCR research

• Uncover new breakthroughs in GPCR structures and their impact on drug discovery

  including structural determination details of the β2 adrenergic receptor–Gs protein complex and the human histamine H1 receptor complex with doxepin

• Identify and understand the role of biased signalling and downstream signalling pathways

  activated by GPCRs and how to translate results into drug discovery programmes

   

• Explore novel approaches to understand allosterism in GPCRs

  plus gain critical case study insights from Novartis, Anchor Therapeutics and Addex Pharma into how they are overcoming the challenges in translating allosteric modulators into later phase drug development

• Discuss the application of novel screening methodologies for GPCRs

  Uncover how label free screening can be applied for phenotypic primary cell analysis, innovative beta arrestin screening strategies and screening methodologies for the identification of allosteric modulators to aid drug discovery

   

• Set your work in context: Utilise the latest discoveries in GPCR science and technology to develop new drug candidate